Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of targeted therapies for patients with cancer and autoimmune diseases. The company leverages its proprietary XpressCites technology to create innovative therapeutics that address significant unmet medical needs. Inhibrx's pipeline includes a diverse range of antibody-drug conjugates and bispecific antibodies, designed to improve efficacy and reduce toxicity compared to traditional therapies. With a robust preclinical and clinical portfolio, their mission is to provide transformative treatment options and improve patient outcomes through cutting-edge science and dedicated research efforts.